1 minute reading time (34 words)

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

Calcitonin gene–related peptide receptor has been implicated in the pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin gene–related peptide receptor antagonist that may be effective in acute migraine treatment.

Related Posts

The AAPM Annual Meeting offers education and networking opportunities for all members of the pain care team.

Learn More